APA (7th ed.) Citation

A, C., HL, W., C, K., R, J., B, K., HP, S., . . . SM, A. (2026). Multicenter Phase I Study of Triapine in Combination with [177Lu]Lutetium-Dotatate in Patients with Well-Differentiated Neuroendocrine Tumors (ETCTN 10388). Clinical cancer research : an official journal of the American Association for Cancer Research, 32(20), 4612. https://doi.org/10.1158/1078-0432.CCR-26-0686

Chicago Style (17th ed.) Citation

A, Chauhan, et al. "Multicenter Phase I Study of Triapine in Combination with [177Lu]Lutetium-Dotatate in Patients with Well-Differentiated Neuroendocrine Tumors (ETCTN 10388)." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 32, no. 20 (2026): 4612. https://doi.org/10.1158/1078-0432.CCR-26-0686.

MLA (9th ed.) Citation

A, Chauhan, et al. "Multicenter Phase I Study of Triapine in Combination with [177Lu]Lutetium-Dotatate in Patients with Well-Differentiated Neuroendocrine Tumors (ETCTN 10388)." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 32, no. 20, 2026, p. 4612, https://doi.org/10.1158/1078-0432.CCR-26-0686.